Eyetech Pharmaceuticals EYET
-
New Morningstar Analyst Report - OSI Pharmaceuticals, Inc.
… acquisition - - and subsequent sale at a major loss - - of Eyetech Pharmaceuticals , casting doubt on the company's ability to enhance ..... opportunities because of the value - destroying acquisition of Eyetech Pharmaceuticals in 2005 . Instead of boosting OSI's top line , Eyetech …
-
OSI Closes Eyetech Acquisition
After much criticism and a slight delay, OSI Pharmaceuticals OSIP completed its acquisition of Eyetech Pharmaceuticals on Monday. We are maintaining our combined-firm fair value estimate of $32 per share. OSI paid just more than $18 per share …
-
Stock Star Rating Performance Update
… Plus World Market CPWM Average/None -33.6% Tempur-Pedic International TPX Average/Narrow -32.1% Eyetech Pharmaceuticals EYET Above Avg./None -24.4% Boston Scientific BSX Average/Wide -24.4% Diebold DBD Below Avg./Narrow …
-
Trial Results Dim QLT's Outlook
… accelerate the expected erosion in Visudyne's market share by prompting doctors to substitute competing therapies like Eyetech's EYET Macugen, which is approved for use across the entire wet AMD patient population. In this study, QLT's Visudyne treatment …
-
We Question an OSI-Eyetech Merger
Although we view OSI's OSIP announced acquisition of Eyetech Pharmaceuticals EYET as merely opportunistic, and financially rather than strategically motivated, we believe OSI shares have been overly penalized …
-
More Concern over QLT's Prospects
… confirm our view that investors should proceed with caution when considering investment in this company. With rival Eyetech's EYET launch of Macugen in late January, QLT's monopoly in wet AMD has clearly ended: Sales of Visudyne slowed dramatically during …
-
OSI to Acquire Eyetech
… placing OSI Pharmaceuticals' OSIP fair value estimate under review while we assess the firm's announced acquisition of Eyetech EYET on Sunday. We're not surprised that Eyetech has agreed to a buyout, as we believe its shares were oversold after news that …
-
Morningstar Rating for Stocks Performance Update
… Past Year's 5-Star Winners and Losers Best Worst Stock Return* Stock Return* Toll Brothers TOL 102% Eyetech Pharmaceuticals EYET -47% Chicago Mercantile Exchange CME 79% Exact Sciences EXAS -45% National Semiconductor NSM 73% Doral …
-
We're Putting QLT Under Review
… for QLT QLTI under review as we transfer analyst coverage. We're also reassessing the competitive landscape now that Eyetech EYET and Pfizer's PFE Macugen has entered the macular degeneration market. We anticipate lowering our fair value estimate for QLT …
-
QLT Still Upbeat on Visudyne
… share as QLT met our expectations for 2004 but could face challenges now that Visudyne's competitor, Macugen from Eyetech EYET , has been approved by the FDA. Visudyne lost its position as the sole treatment for wet age-related macular degeneration …